Skip to main content
Premium Trial:

Request an Annual Quote

Incyte Licenses Key Microarray, Gene Expression Patents to Agilent

NEW YORK, Nov. 5 – Incyte Genomics said Monday that it had licensed its main microarray and gene expression patents to Agilent Technologies, a manufacturer of printed DNA microarrays.

Under the terms of the licensing agreements, Incyte will provide Agilent with its patents for nucleic acid linear amplification, the manufacture and use of DNA microarrays, and the use of gene expression arrays in cancer research and diagnosis. 

Incyte has also exclusively licensed to Agilent its patent portfolio for inkjet array manufacture, including patents for in situ  synthesis of nucleic acid microarrays. 

"We are pleased to add the Incyte patents to the already extensive portfolio of Agilent patents and patent licenses," Barney Saunders, vice president and general manager of Agilent's Bio-Research Solutions, said in a statement.

"These patents will consolidate and strengthen Agilent's position as a major manufacturer of printed DNA microarrays and as a supplier of reagents and kits for sample preparation," Saunders said. 

Financial terms of the deal were not disclosed.

In January, Agilent opened a 15,000-square-foot DNA microarray production facility as part of its efforts to expand its microarray manufacturing program, which included plans to ship over one million microarrays per year by 2002.

As part of that effort, Agilent also previously signed a deal for access to Incyte’s cDNA clones and its Lifeseq data for use on the company’s off-the-shelf arrays.

Both Agilent and Incyte are based in Palo Alto, Calif.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.